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Large traditional clinical trials suggest that sodium-glucose co-transporter 2 inhibitors improve symptoms in patients with heart
failure and reduced ejection fraction (HFrEF) and in patients with heart failure and preserved ejection fraction (HFpEF). In the
midst of the Coronavirus Disease 2019 pandemic, we sought to confirm these benefits in a new type of trial that was patient centered and conducted in a completely remote fashion. In the CHIEF-HF trial (NCT04252287), 476 participants with HF, regardless
of EF or diabetes status, were randomized to 100 mg of canagliflozin or placebo. Enrollment was stopped early due to shifting
sponsor priorities, without unblinding. The primary outcome was change in the Kansas City Cardiomyopathy Questionnaire Total
Symptom Score (KCCQ TSS) at 12 weeks. The 12-week change in KCCQ TSS was 4.3 points (95% confidence interval, 0.8–7.8;
P = 0.016) higher with canagliflozin than with placebo, meeting the primary endpoint. Similar effects were observed in participants with HFpEF and in those with HFrEF and in participants with and without diabetes, demonstrating that canagliflozin significantly improves symptom burden in HF, regardless of EF or diabetes status. This randomized, double-blind trial, conducted
without in-person interactions between doctor and patient, can serve as a model for future all-virtual clinical trials.

T

he costs of conducting clinical trials have risen substantially
over time, leading to calls for novel study designs to generate the evidence needed to guide care1–3. A large component
(up to 50%) of these costs is the burden of data collection on sites,
which have nearly quadrupled from 1990 to 2010 (ref. 4). The ongoing Coronavirus Disease 2019 (COVID-19) global pandemic further highlighted the challenges of traditional study designs that
depend on in-person visits and resource-intense data acquisition
and verification. In response to the growing demands to make
clinical trials more pragmatic, novel study designs have been implemented, from leveraging existing registries for data collection5 to
the use of electronic health records to identify, enroll, randomize
and follow-up eligible patients6,7. Although the innovation of eliminating in-person clinical trial visits has been proposed, it has not, to
our knowledge, been tested on a large scale.
Heart failure (HF) is a common, chronic condition with a high
burden of debilitating symptoms, physical limitations and poor
quality of life. Many approved HF therapies have neutral or modest
effects on symptoms, making treatments that address this key goal of
management a critical unmet need. Sodium-glucose co-transporter
2 inhibitors (SGLT2is) not only reduce cardiovascular death and
hospitalization in patients with HFrEF and in patients with HFpEF,
but they have also recently been shown to improve health status
(symptoms, function and quality of life)8–16. Given the importance
of symptoms, function and quality of life to patients, confirming these health status benefits across the spectrum of HF, and in
patients with and without diabetes, can underscore the importance
of increasing their use in routine care.

Addressing the call both for more efficient and cost-effective
clinical trials and to confirm the health status benefits of SGLT2is in
patients with HF of all types, Canagliflozin: Impact on Health Status,
Quality of Life and Functional Status in Heart Failure (CHIEF-HF)
was designed to be a completely decentralized trial without any
in-person interaction with participants.

Results

Study design. In light of regulatory shifts that have increased
the priority of patient-reported outcomes in approving new
medications17, and the recent qualification of the Kansas City
Cardiomyopathy Questionnaire (KCCQ) as a clinical outcome
assessment18, CHIEF-HF was designed to test the primary hypothesis that canagliflozin, compared to placebo, would improve the
KCCQ Total Symptom Score (TSS) at 12 weeks. Given the ability to
collect the KCCQ via smart devices, CHIEF-HF was designed as a
completely decentralized, virtual (that is, no in-person visits) study
with direct engagement of patients through a study website, electronic informed consent, direct home delivery of study medication,
completion of the primary endpoint by a mobile application and a
Fitbit to monitor activity. To ensure protection of participants’ personal health information (PHI), the mobile application was compliant with 21 CFR part 11 with access only by study participants; all
potential sources of PHI collection were disclosed in the consent
process; PHI was firewalled from the sponsor and contract research
organization; and insurance claim information was presented in
de-identified formats. Eighteen health systems were selected to participate (Supplementary Note 1) and agreed to the use of a central
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Fig. 1 | Study CONSORT diagram showing the process of subject participation. KCCQ, Kansas City Cardiomyopathy Questionnaire.

institutional review board (Advarra). Eligible patients were centrally
randomized 1:1 using a computer-generated randomization schedule, stratified by the type of heart failure (HFrEF or HFpEF), to
either canagliflozin 100 mg daily or matching placebo for 12 weeks,
which was shipped directly to participants. Further details regarding
randomization are provided in the study protocol as supplementary
materials. The study app asked patients, each week, to report the
number of days they took the study drug. The original sample size
was to include 1,900 randomized participants, but shifting priorities
of the sponsor (Janssen Scientific Affairs) led to administrative closing of the study by the sponsor to enrollment on 12 February 2021.
This decision was made without an interim analysis of unblinded
data or recalculation of sample sizes and power and was in consultation with the Academic Steering Committee.

Study execution. Among the 448 randomized participants included
in the intention-to-treat analyses, all received their study medication and Fitbit (Supplementary Table 1). The diagnosis of HF was
confirmed by claims data in all participants. The compliance with
completing an eDiary of medication use was 95%, and 91% reported
taking more than 80% of their study medications. Participants’ Fitbit
data transmissions indicated that 94% wore their Fitbit 70% or more
of the time. The KCCQ data were very complete, being completed
more than 97% of the time at each scheduled assessment.

Baseline characteristics. Participants were recruited between
26 March 2020 and 12 February 2021. Among 476 participants randomized, 21 immediately withdrew without ever taking study medications, and seven did not provide a follow-up
KCCQ, resulting in 448 participants being included in the primary intention-to-treat analyses, of whom 222 were randomized
to canagliflozin and 226 to placebo (Fig. 1). Baseline characteristics of these 448 participants are detailed in Table 1 and were
well balanced between treatment groups. Overall, mean age was
63.4 ± 13.3 years (range, 20–94); 84% of participants were White;
45% of participants were women; 28% of participants had type 2
diabetes; and 60% of participants had HFpEF. At 12 weeks, KCCQ
scores were available in 414 participants (92.4%), 206 randomized
to placebo and 208 to canagliflozin.

Outcomes. The baseline KCCQ TSS was 58 ± 21 in participants
randomized to placebo and 57.4 ± 21 in participants randomized
to canagliflozin. At 12 weeks, both groups had improvements in
their scores, to 63.2 ± 22 and 67.1 ± 22, with changes of 5.2 ± 20 and
8.9 ± 20 in the placebo and canagliflozin groups, respectively. Figure
2 and Table 2 show the changes in scores over time, which begin to
separate at 2 weeks. The mean difference in the changes in scores
at 12 weeks was 4.3 points (95% confidence interval (CI), 0.8–7.8;
P = 0.016) in favor of canagliflozin. Extended Data Fig. 1 shows the
proportions of patients with different magnitudes of clinical change.
A larger number of patients deteriorated by a moderate or greater
amount on placebo, whereas a larger number of participants had
moderate to large improvements with canagliflozin. Improvements
in mean scores were also observed for most other KCCQ domains
but not for changes in step counts, which did not change over 12
weeks in either group (mean difference favoring canagliflozin of
29.8 steps (95% CI, −284 to 344)).
The effects of canagliflozin on the change in the KCCQ TSS
at 12 weeks were consistent in patients with HFrEF (4.0; 95% CI,
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Table 1 | Baseline characteristics
Canagliflozin

Total

226

222

448

Mean (s.d.)

64.0 (13.45)

62.9 (13.19)

63.4 (13.32)

Median

66.0

65.0

66.0

Range

(22; 94)

(20; 89)

(20; 94)

18–25

2 (0.9%)

4 (1.8%)

6 (1.3%)

26–50

38 (16.8%)

35 (15.8%)

73 (16.3%)

51–64

59 (26.1%)

68 (30.6%)

127 (28.3%)

≥65

127 (56.2%)

115 (51.8%)

242 (54.0%)

97 (42.9%)

104 (46.8%)

201 (44.9%)

Sample size
Age (years)

Gender
Female
Race
White

194 (85.8%)

182 (82.0%)

376 (83.9%)

Black or African
American

30 (13.3%)

35 (15.8%)

65 (14.5%)

Asian

1 (0.4%)

1 (0.5%)

2 (0.4%)

1 (0.4%)

4 (1.8%)

5 (1.1%)

Type 2 diabetes
mellitus

59 (26.1%)

66 (29.7%)

125 (27.9%)

Non-type 2
diabetes mellitus

167 (73.9%)

156 (70.3%)

323 (72.1%)

Other
Diabetes

LS mean ± s.e.

Placebo

P value for difference at week 12 = 0.016

10
8
6
4
2
0
–2
0
Number of participants
Placebo 226
Canagliflozin 221

2

4

6
Week

12

222
221

215
215

209
208

206
207

Placebo

Canagliflozin

Fig. 2 | KCCQ TSS over time. Mean changes in KCCQ TSSs (error bars
represent standard errors) at 2, 4, 6 and 12 weeks after randomization.

12-week treatment period. No diabetic ketoacidosis or lower limb
amputations occurred (Table 3).

Discussion

Safety. Serious adverse events and death are summarized in
Supplementary Tables 2 and 3. Based on the claims data, 9.9%
(45/455) of participants had a serious adverse event (emergency
room visit or hospitalization) through week 12 (27 (12.1%) in
canagliflozin and 18 (7.8%) in placebo). Four participants randomized to the canagliflozin group and two randomized to the placebo group were hospitalized for HF. Six participants (two in the
canagliflozin group and four in the placebo group) died during the

The results of this trial demonstrate the feasibility of a decentralized,
virtual study design that was successfully launched and executed
during the COVID-19 pandemic and which adds considerable new
insights into the health status effects of SGLT2is in HF. Improving
symptom burden is a critical goal for HF management. CHIEF-HF,
a randomized, placebo-controlled trial accomplished without any
in-person visits, demonstrated that canagliflozin resulted in a rapid
and clinically meaningful improvement in the symptoms of patients
with HF, as quantified by the KCCQ. This benefit was consistent
across the range of EF and in patients with and without type 2 diabetes. Although canagliflozin does not have an HF indication, this
study adds important supporting evidence about the beneficial
effects of the class of SGLT2 inhibitors on improving HF symptoms,
with novel data indicating that these benefits can occur as early as
2 weeks after initiation of therapy.
The fact that CHIEF-HF launched 2 weeks before a national
shutdown due to the COVID-19 pandemic highlights the potential
advantages of a decentralized, virtual clinical trial19. Underscoring
the challenge of research in the COVID-19 era, the US Food & Drug
Administration20 and a Heart Failure Collaboratory Statement21
have highlighted the need to prioritize safety, even if sacrificing
protocol adherence. Because the primary outcome was the KCCQ,
and given the well-established safety of the SGLT2i class, the study
drug was distributed remotely, and the outcomes were collected
virtually on participants’ phones. In fact, the ability to use a smartphone app to enroll and collect KCCQ and adherence data with
good data quality supported recruitment that was five times faster
than the average enrollment rate in HF trials22. Of course, the use of
mobile technology can introduce potential selection biases, from
requiring patients to own (potential socio-economic biases) and
be able to use (potential age and cognitive biases) a smart device,
although access to such devices are growing over time. Future
studies examining interventions to improve the health status of
patients can consider such an approach, if there are no anticipated
safety concerns that might require sequential monitoring with
blood work or imaging tests. The CHIEF-HF trial also modeled
how an SGLT2i could be safely initiated without a requirement for
in-person visits and, if desired, patients’ health status monitored
remotely to assess its effect.
The findings of this study augment a growing body of literature on the benefits of SGLT2is in patients with HF. Several large
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Randomization stratification
HFpEF

135 (59.7%)

132 (59.5%)

267 (59.6%)

HFrEF

91 (40.3%)

90 (40.5%)

181 (40.4%)

Total symptom
score

58.0 ± 21.1

57.4 ± 21.3

57.7 ± 21.2

Overall
summary score

52.7 ± 18.3

51.6 ± 18.8

52.1 ± 18.5

Clinical
summary score

56.3 ± 19.5

54.6 ± 19.7

55.5 ± 19.6

Physical
limitation score

54.4 ± 21.5

51.9 ± 21.2

53.1 ± 21.4

Social limitation 50.9 ± 22.4
score

50.9 ± 23.8

50.9 ± 23.1

47.4 ± 21.8

45.8 ± 21.2

46.6 ± 21.5

KCCQ scores

Quality of life
score
Step counts

4,041.4 ± 2,774.9 4,583.8 ± 3150.5 4,310.1 ± 2,975.8

−1.0 to 9.0) and HFpEF (4.5; 95% CI, −0.3 to 9.4) (P value for
interaction = 0.35; Fig. 3). Similar benefits were also observed in
participants with type 2 diabetes (6.5; 95% CI, −0.2 to 13.2) and
participants without type 2 diabetes (3.6; 95% CI, −0.5 to 7.8)
(P value for interaction = 0.90).
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Table 2 | Primary outcome—KCCQ TSS
Observed values
Placebo

Change from baseline

Canagliflozin

Placebo

Canagliflozin

Difference of change

LS mean (s.e.)

LS mean (s.e.)

LS mean (s.e.)

95% CI

3.4 (1.03)

6.1 (1.03)

2.7 (1.44)

(−0.1, 5.5)

n

Mean (s.d.)

n

Mean (s.d.)

Baseline

226

58.0 (21.12)

221

57.4 (21.32)

Week 2

222

61.5 (21.21)

222

63.5 (20.90)

Week 4

215

62.1 (21.50)

216

64.5 (21.01)

4.1 (1.10)

7.1 (1.10)

3.0 (1.54)

(−0.0, 6.1)

Week 6

209

64.8 (21.44)

209

65.0 (21.62)

6.4 (1.13)

7.6 (1.13)

1.2 (1.59)

(−1.9, 4.3)

Week 12

206

63.2 (22.32)

208

67.1 (22.19)

4.9 (1.27)

9.2 (1.27)

4.3 (1.78)

(0.8, 7.8)

P value

0.016

The LS means, standard errors, 95% CIs and P values are based on a repeated-measures, mixed-effects ANCOVA model with treatment, stratification factor (HFrEF or HFpEF), time, time by treatment and
baseline KCCQ TSS values as covariates, with an unstructured covariance structure.

Table 3 | Secondary outcomes
Observed values

Change from baseline

Placebo

Canagliflozin

Placebo

Canagliflozin

Difference of change

n

n

Mean (s.d.)

LS mean (s.e.)

LS mean (s.e.)

LS mean (s.e.)

95% CI

208

61.7 (22.22)

6.2 (1.18)

9.5 (1.18)

3.3 (1.66)

(0.0, 6.6)

208

63.7 (21.81)

4.7 (1.16)

8.5 (1.17)

3.7 (1.64)

(0.5, 7.0)

59.5 (23.00)

204

60.5 (23.58)

4.8 (1.26)

7.8 (1.27)

3.0 (1.78)

(−0.5, 6.5)

56.3 (24.88)

208

58.9 (23.51)

9.1 (1.40)

12.4 (1.41)

3.3 (1.98)

(−0.5, 7.2)

204

60.3 (27.49)

6.2 (1.48)

8.8 (1.48)

2.6 (2.08)

(−1.4, 6.7)

205

4,480.5 (3,033.79)

−74.9 (112.85)

−45.1 (113.78)

29.8 (159.84)

(−284.4, 344.1)

Mean (s.d.)

KCCQ domain scores
Overall summary score
Week 12

206

59.1 (21.39)

Clinical summary score
Week 12

206

61.3 (20.75)

Physical limitation score
Week 12

206

Quality of life score
Week 12

206

Social limitation score
Week 12

202

57.2 (26.15)

Total daily step counts
Week 12

208

4,013.6 (2,624.28)

The LS means, standard errors, 95% CIs and P values are based on a repeated-measures, mixed-effects ANCOVA model with treatment, stratification factor (HFrEF or HFpEF), time, time by treatment and
baseline KCCQ TSS values as covariates, with an unstructured covariance structure.

clinical trials have documented reduced cardiovascular mortality
and hospitalizations in patients with HFrEF with this class, regardless of type 2 diabetes8,10, and a recent trial demonstrated a clinical
benefit of empafligozin in patients with HFpEF14,16. Several trials
with dapafliglozin demonstrated a similar magnitude of improvement in patients’ health status in HFrEF and HFpEF, as found in
CHIEF-HF9,13. CHIEF-HF findings agree closely with these previous observations in terms of the magnitude of benefit in HFrEF, but
it is, to our knowledge, the first to demonstrate an early benefit on
participants’ health status in a broad spectrum of patients with HF,
including those with HFpEF. Collectively, these data indicate that
the use of SGLT2i not only improves prognosis but also meaningfully improves symptoms, function and quality of life.
There have been concerns that the COVID-19 pandemic might
alter patient-reported outcomes independently of any treatment
effect23. In fact, the largest effect of treatment was observed in the
symptom scale of the KCCQ, with slightly lesser effects on physical and social limitations. Whether these domains were affected by
other factors, such as home isolation, is unknown, and the minimal changes in step counts might have been affected by behavior
changes in the setting of COVID-19. Future studies will need to
define the effect of SGLT2is on measures of physical activity. It is

also noteworthy that the symptoms improved in patients treated
with placebo. Although this might be considered a placebo effect, it
is also possible that participants’ adherence to other HF medications
improved during the trial, given that they had weekly reminders for
reporting their medication use.
These findings should be interpreted in the context of several
potential limitations. First, the trial design originally planned for
1,900 patients to have 95% power to detect a treatment benefit of
3 points, which was arguably overpowered. Thus, although study
enrollment stopped early, a statistically significant benefit of treatment was still detected. Second, although the enrollment of women
and minorities is higher than in most previous SGLT2i trials,
including 15% African American participants, additional studies in
these populations are warranted. Third, the study was not designed
or powered to examine clinical events, which have been studied in
other trials. In addition, given its unique design, there were no case
report forms in this study, and less detailed clinical and comorbidity
data are available. Future trials using this approach might want to
design a more detailed case report form to be completed at screening by sites, although this would increase the burden and costs of
the trial. Finally, the nature of the study design precluded capturing biomarker or imaging data that could potentially illuminate the
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LS mean diff.
(95% CI)

LS mean difference (95% CI)
All participants

4.3 (0.8, 7.8)

Strata
HFpEF

4.5 (–0.3, 9.4)

HFrEF

4.0 (–1.0, 9.0)

Cohort
Non-T2DM

3.6 (–0.5, 7.8)

T2DM

6.5 (–0.2, 13.2)
–10

←Placebo better

–5

0

5

10

15

20

Canagliflozin better→

Fig. 3 | Effects of treatment by HF type and diabetes status. Estimates of
the mean difference in KCCQ TSSs by subgroups are stratified by EF and
diabetes status. In total, 208 participants were treated with canagliflozin
and 206 with placebo. T2DM, type 2 diabetes mellitus.

potential mechanisms of benefit, and changes in concomitant medications were not captured, although the short duration of the trial
likely minimized the importance of this latter concern.
In conclusion, the CHIEF-HF study executed a novel, decentralized, double-blind, randomized controlled trial design focusing on
patient-centered outcomes. It also demonstrates the benefits of canagliflozin in significantly improving patients’ symptom burden, regardless of EF or type 2 diabetes status, further underscoring the benefits
of SGLT2is in addressing a key treatment goal for patients with HF.
Such novel approaches to generating important evidence offer the
potential for future clinical trials to lower the cost and increase the
speed of acquiring new evidence to improve clinical practice.

Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of
author contributions and competing interests; and statements of
data and code availability are available at https://doi.org/10.1038/
s41591-022-01703-8.
Received: 6 September 2021; Accepted: 13 January 2022;
Published online: 28 February 2022

References

1. Fordyce, C. B. et al. Cardiovascular drug development: is it dead or just
hibernating? J. Am. Coll. Cardiol. 65, 1567–1582 (2015).
2. Lauer, M. S., Gordon, D., Wei, G. & Pearson, G. Efficient design of clinical
trials and epidemiological research: is it possible? Nat. Rev. Cardiol. 14,
493–501 (2017).
3. Antman, E. M. & Harrington, R. A. Transforming clinical trials in
cardiovascular disease: mission critical for health and economic well-being.
JAMA 308, 1743–1744 (2012).
4. Berndt, E. & Cockburn, I. Price Indexes for Clinical Trial Research: A
Feasibility Study. NBER Working Papers 18918 https://ideas.repec.org/p/nbr/
nberwo/18918.html (National Bureau of Economic Research, 2013).
5. Frobert, O. et al. Thrombus Aspiration in ST-Elevation myocardial infarction
in Scandinavia (TASTE trial). A multicenter, prospective, randomized,
controlled clinical registry trial based on the Swedish angiography and
angioplasty registry (SCAAR) platform. Study design and rationale. Am.
Heart J. 160, 1042–1048 (2010).

Nature Medicine | VOL 28 | April 2022 | 809–813 | www.nature.com/naturemedicine

6. Marquis-Gravel, G. et al. Rationale and design of the Aspirin Dosing—A
Patient-Centric Trial Assessing Benefits and Long-term Effectiveness
(ADAPTABLE) trial. JAMA Cardiol. 5, 598–607 (2020).
7. Jones, W. S. et al. Comparative effectiveness of aspirin dosing in
cardiovascular disease. N. Engl. J. Med. 384, 1981–1990 (2021).
8. McMurray, J. J. V. et al. Dapagliflozin in patients with heart failure and
reduced ejection fraction. N. Engl. J. Med. 381, 1995–2008 (2019).
9. Nassif, M. E. et al. Dapagliflozin effects on biomarkers, symptoms, and
functional status in patients with heart failure with reduced ejection fraction:
the DEFINE-HF Trial. Circulation 140, 1463–1476 (2019).
10. Packer, M. et al. Cardiovascular and renal outcomes with empagliflozin in
heart failure. N. Engl. J. Med. 383, 1413–1424 (2020).
11. Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in
type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).
12. Petrie, M. C. et al. Effect of dapagliflozin on worsening heart failure and
cardiovascular death in patients with heart failure with and without diabetes.
JAMA 323, 1353–1368 (2020).
13. Kosiborod, M. N. et al. Effects of dapagliflozin on symptoms, function, and
quality of life in patients with heart failure and reduced ejection fraction:
results from the DAPA-HF trial. Circulation 141, 90–99 (2020).
14. Anker, S. D. et al. Empagliflozin in heart failure with a preserved ejection
fraction. N. Engl. J. Med. 385, 1451–1461 (2021).
15. Nassif, M.E. et al. The SGLT2 inhibitor dapagliflozin in heart failure with
preserved ejection fraction: a multi-center randomized trial. Nat. Med. 27,
1954–1960 (2021).
16. Bhatt, D. L. et al. Sotagliflozin in patients with diabetes and recent worsening
heart failure. N. Engl. J. Med. 384, 117–128 (2020).
17. US Food & Drug Administration. Treatment for Heart Failure: Endpoints for
Drug Development Guidance for Industry. https://www.fda.gov/regulatoryinformation/search-fda-guidance-documents/treatment-heart-failure-endpoints
-drug-development-guidance-industry (US Food & Drug Administration, 2019).
18. DDT COA #000084: Kansas City Cardiomyopathy Questionnaire (KCCQ).
Clinical Outcome Assessments (COA) Qualification Submissions Office of
Cardiology, Hematology, Endocrinology, and Nephrology (OCHEN) Division
of Cardiovascular and Nephrology (DCN). https://www.fda.gov/drugs/
clinical-outcome-assessment-coa-qualification-program/ddt-coa-000084kansas-city-cardiomyopathy-questionnaire-kccq (2020).
19. Executive Office of the President. Declaring a national emergency concerning
the novel coronavirus disease (COVID-19) outbreak. Proclamation 9994.
https://www.federalregister.gov/documents/2020/03/18/2020-05794/
declaring-a-national-emergency-concerning-the-novel-coronavirus-diseasecovid-19-outbreak (2020).
20. US Food & Drug Administration. FDA Guidance on Conduct of Clinical
Trials of Medical Products During the COVID-19 Public Health Emergency.
https://www.fda.gov/regulatory- information/search-fda-guidancedocuments/fda-guidance-conduct-clinical-trials-medical- products-duringcovid-19-public-health-emergency (US Food & Drug Administration, 2020).
21. Abraham, W., Fiuzat, M., Psotka, M. & O’Connor, C. Heart failure
collaboratory statement on clinical trials in the landscape of COVID-19.
JACC Heart Fail. 8, 423–425 (2020).
22. Samman Tahhan, A. et al. Trends in heart failure clinical trials from
2001–2012. J. Card. Fail. 22, 171–179 (2016).
23. Lindenfeld, J. et al. Haemodynamic-guided management of heart failure
(GUIDE-HF): a randomised controlled trial. Lancet 398, 991–1001 (2021).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long
as you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The images or other
third party material in this article are included in the article’s Creative Commons license,
unless indicated otherwise in a credit line to the material. If material is not included in
the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2022

813

Articles
Methods

Study population. The design of the CHIEF-HF study was previously described,
and all patients provided informed consent24. A central institutional review
board (Advarra) approved the study. The complete inclusion and exclusion
criteria are provided in the study protocol, along with the statistical analysis plan,
as supplementary material. In brief, different recruitment sites used different
strategies for identifying patients to participate, including email, patient portals
through the health system’s electronic medical record, phone calls and contacting
providers before a scheduled visit. Potential participants expressed interest in
enrolling and confirmed that they were in sole possession of an Apple iPhone
6 (or later) or a Samsung Galaxy phone and were willing to wear a Fitbit device
(Fitbit Versa 2). The site principal investigators then confirmed study inclusion
criteria (the screening process), including a diagnosis of HF (HFrEF with an
EF < 40% and a primary or 2 HF diagnosis in any position within 18 months;
HFpEF with an EF ≥ 40% and similar diagnosis codes as HFrEF and treatment
with a loop diuretic or mineralocorticoid receptor antagonist). They also
confirmed that no exclusion criteria were present, including no use of an SGLT2i
within 3 months, no history of diabetic ketoacidosis or type 1 diabetes and an
estimated glomerular filtration rate <30 ml min−1. Eligible patients then provided
electronic informed consent via the app, after reviewing it over the phone with
the site principal investigator. Once consented, they completed the KCCQ on the
study app. Those with an overall summary score of 80 or lower were then enrolled
and randomized. Of 658 participants who consented, 182 (27.6%) were excluded
based on their KCCQ scores.
Outcomes. The primary outcome was change in the KCCQ TSS—a domain of
the KCCQ scale that quantifies patient symptom frequency and severity over the
past 2 weeks. The KCCQ scale has extensive data supporting its validity, reliability,
sensitivity to clinical change and association with other clinical events, including
HF hospitalization and death25–30. The KCCQ was collected at screening and at 2,
4, 6 and 12 weeks after randomization. Scores are transformed from 0 points (the
worst) to 100 points. Although lower thresholds for minimal clinically important
differences in the KCCQ have been reported31, changes of 5, 10 and 20 points
are generally considered to represent small (but clinically important), moderate
to large and large to very large clinical changes, respectively.32–34 A shift of one
response category in a symptom-informative question increases the TSS by 2.08–
4.2 points, depending on the item, meaning that a 5-point change requires a net
improvement of at least two responses34.
Secondary endpoints included change from baseline in the 2-week average of
daily step counts acquired from the Fitbit and changes in other domain scores of
the KCCQ scores at 12 weeks. Adverse event reporting was collected from patients
by self-report through the coordinating center, and serious adverse events were
collected through claims data. Vital status was obtained at the end of the study in
those lost to follow-up.
Statistical analyses. The original protocol was approved on 7 November 2019 and
amended on 7 February 2020 (to remove the original plan to return study results
to patients) and again on 2 June 2020 (to remove an initial exclusion of those
with a KCCQ overall summary score <40 and to add mineralocorticoid receptor
antagonists as confirmation of an HFpEF diagnosis). The Statistical Analysis Plan
was developed on 10 April 2020 and finalized before database lock on 21 July 2021.
The Protocols and Statistical Analysis Plan are provided in Supplementary Note 2.
Because of the novel study design, it was anticipated that some patients would
sign up for the study but not ultimately participate. Thus, the intention-to-treat
analysis was based on all randomized patients who took at least one dose of the
study drug and had at least one post-randomization KCCQ (full analysis set). A
valid post-randomization KCCQ TSS, which was the primary endpoint of the
study, was required for the intention-to-treat analysis to test changes in KCCQ TSS.
The safety analysis set included all randomized patients who took at least one dose
of the study drug (safety analysis set). Baseline data are reported as means ± s.d.
and categorical variables as frequencies. Outcome data are reported as means ± s.d.
with 95% CIs. The mechanics of study excecution are described as the frequency of
complete data collection and self-reported medication adherence.
The primary outcome—change in the KCCQ TSS—was assessed with a
mixed-effects model for repeated measures (MMRM) that included treatment
(canagliflozin or placebo), stratification (HFrEF versus HFpEF), time,
time-by-study intervention interaction and baseline KCCQ TSS score, using an
unstructured covariance matrix. Least squares (LS) mean differences and 95%
CIs were estimated at week 12 for placebo versus canagliflozin. This was repeated
for key pre-specified subgroups: HFrEF versus HFpEF and participants with and
without type 2 diabetes. To support clinical interpretation of the mean differences
in scores, the distribution of patients with different clinical magnitudes of change
were calculated. Although imputation approaches were planned for, the very high
completion of the KCCQ did not require their use. The key secondary outcome of
daily step count was to be analyzed hierarchically after the primary outcome using
the same MMRM method, as were the other KCCQ domains. No P values are
reported for the secondary analyses because the smaller-than-planned sample size
left no room for additional analyses; this also aligns with current recommendations
to minimize the reporting of P values35. Analyses were conducted by Janssen and

Nature Medicine
independently validated at Saint Luke’s Mid America Heart Institute. SAS version
9.4 software was used, and two-sided P values less than 0.05 were considered
statistically significant.
The trial was sponsored by Janssen Scientific Affairs. The sponsor participated
in the design and conduct of the study; the collection, management, analysis
and interpretation of the data; the review of the manuscript; and the decision to
submit the manuscript for publication. The sponsor did not have the right to veto
publication and did not have control regarding the journal to which the paper
was submitted.
Reporting Summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.

Data availability

Requests for access to the study data can be made through Yale Open Data Access
(http://yoda.yale.edu) 18 months after completion of the trial, which is 1 March
2022 (last contact for extended follow-up).
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Extended Data Fig. 1 | Distributions of 3-month Changes in KCCQ Total Symptom Scores. The proportions of patients experiencing the indicated
magnitudes of clinical change are shown. KCCQ=Kansas City Cardiomyopathy Questionnaire.
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